title: Evaluation of the ability of Streptococcus agalactiae strains isolated from genital and neonatal specimens to bind to human fibrinogen and correlation with characteristics of the fbsA and fbsB genes.
abstract: The ability of 111 Streptococcus agalactiae strains to bind to human fibrinogen was quantified. We correlated the percentages of bacteria that bound to immobilized fibrinogen with fibrinogen-binding (fbs) gene characteristics of strains and with clinical origin, serotypes, and phylogenetic positions of strains. Percentages varied from 0.4 to 29.9%. Fifty-five strains (49.5%) had the fbsB gene sensu stricto described by Gutekunst et al. (Infect. Immun., 72:3495-3504, 2004), allowing adhesion to human fibrinogen, and all of the other strains had an fgag variant gene. Ninety strains (81.1%) had a fbsA gene and 55 of them also had the fbsB gene. The other 21 strains (18.9%) had a truncated form of fbsA without the fbsB gene sensu stricto. The numbers of 48-nucleotide repeat sequences (rs) in the fbsA gene varied from 2 to 26. The population of strains with the highest ability to bind to human fibrinogen significantly more frequently had the fbsB gene sensu stricto and 4 to 7 rs in the fbsA gene (P < 0.05). However, the single strain that carried the highest number of rs (26 rs) in the fbsA gene showed high fibrinogen-binding activity (24.3%). Strains exhibiting significantly higher levels of binding to human fibrinogen belonged to a phylogenetic group of strains associated with neonatal meningitis, currently known as the ST-17 clone, that is mostly composed of serotype III strains. These findings indicate that S. agalactiae strains possess a wide variety of fbs gene content that markedly influences the ability of strains to bind to human fibrinogen. Variations in the configuration and the expression of the Fbs proteins may therefore partly explain the variability of virulence in S. agalactiae species.
authors.affiliation: Equipe d'Accueil 3854, Bactéries et risque maternofoetal, UFR Médecine, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours Cedex, France. rosenau@med.univ-tours.fr
authors.forename: Agnès
authors.initials: A
authors.lastname: Rosenau
authors.forename: Karine
authors.initials: K
authors.lastname: Martins
authors.forename: Souheila
authors.initials: S
authors.lastname: Amor
authors.forename: François
authors.initials: F
authors.lastname: Gannier
authors.forename: Philippe
authors.initials: P
authors.lastname: Lanotte
authors.forename: Nathalie
authors.initials: N
authors.lastname: van der Mee-Marquet
authors.forename: Laurent
authors.initials: L
authors.lastname: Mereghetti
authors.forename: Roland
authors.initials: R
authors.lastname: Quentin
mesh_terms: D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism*; D001665:Binding Sites / Q000235:genetics; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005340:Fibrinogen / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007231:Infant, Newborn; D011485:Protein Binding / Q000235:genetics; D013292:Streptococcus agalactiae / Q000235:genetics / Q000254:growth & development / Q000302:isolation & purification* / Q000378:metabolism*; D014621:Vagina / Q000378:metabolism* / Q000382:microbiology*
chemical_list: D001426:Bacterial Proteins; D002352:Carrier Proteins; C499709:FbsA protein, Streptococcus agalactiae; C487204:FbsB protein, Streptococcus agalactiae; D005340:Fibrinogen